Literature DB >> 70287

Serum FSH, LH and prolactin in normal males and patients with prostatic diseases.

G L Hammond, M Kontturi, P Määttälä, M Puukka, R Vihko.   

Abstract

Serum FSH, LH and prolactin were measured in fifty-eight normal males between 30 and 80 years of age. At the same time similar estimations were performed on samples taken from 232 patients with benign prostatic hypertrophy (BPH) and twenty-six patients with prostatic carcinoma. The three groups were compared with respect to age, and it was observed that significant rises related to age occurred in the serum levels of FSH, LH and prolactin in normal men after the sixth decade. The patient groups did not differ significantly from each other, or from the normal age-matched population in respect to prolactin and FSH levels. Serum LH in both the carcinoma and BPH patient groups, however, differed significantly from the controls, and remained at the level associated with younger normal males. It is suggested that testosterone metabolites from the prostate exert a negative feedback on pituitary LH secretion.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 70287      PMCID: PMC8332699          DOI: 10.1111/j.1365-2265.1977.tb01304.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  7 in total

1.  Preoperative Plasma Levels of Total Testosterone Associated with High Grade Pathology-Detected Prostate Cancer: Preliminary Results of a Prospective Study in a Contemporary Cohort of Patients.

Authors:  Antonio B Porcaro; Nicolò De Luyk; Paolo Corsi; Marco Sebben; Alessandro Tafuri; Giovanni Cacciamani; Davide De Marchi; Irene Tamanini; Davide Inverardi; Matteo Brunelli; Maria A Cerruto; Gian L Salvagno; Gian C Guidi; Walter Artibani
Journal:  Curr Urol       Date:  2017-05-30

2.  Comparison of megestrol acetate and clomiphene citrate as supplemental medication in postmenopausal oestrogen replacement therapy.

Authors:  A Kauppila; S Kivinen; P Leinonen; R Tuimala; R Vihko; P Ylöstalo
Journal:  Arch Gynecol       Date:  1983

3.  Plasma steroid and protein hormone concentrations in patients with benign prostatic hypertrophy and in normal men.

Authors:  E Ortega; E Ruiz; M C Mendoza; A Martin-Andres; C Osorio
Journal:  Experientia       Date:  1979-06-15

4.  Targeting stromal androgen receptor suppresses prolactin-driven benign prostatic hyperplasia (BPH).

Authors:  Kuo-Pao Lai; Chiung-Kuei Huang; Lei-Ya Fang; Kouji Izumi; Chi-Wen Lo; Ronald Wood; Jon Kindblom; Shuyuan Yeh; Chawnshang Chang
Journal:  Mol Endocrinol       Date:  2013-07-26

5.  Placental transfer and hormonal effects of metoclopramide.

Authors:  P Arvela; R Jouppila; A Kauppila; A Pakarinen; O Pelkonen; R Tuimala
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  Simultaneous Measurements of Follicle Stimulating Hormone and Total Testosterone and Associations in Clinically Localized Prostate Cancer.

Authors:  Antonio B Porcaro; Salvatore Siracusano; Nicolò de Luyk; Paolo Corsi; Marco Sebben; Alessandro Tafuri; Tania Processali; Davide Inverardi; Giovanni Cacciamani; Daniele Mattevi; Maria A Cerruto; Matteo Brunelli; Claudio Ghimenton; Carmelo Monaco; Walter Artibani
Journal:  Curr Urol       Date:  2017-10-22

7.  Prostate cancer volume associates with preoperative plasma levels of testosterone that independently predicts high grade tumours which show low densities (quotient testosterone/tumour volume).

Authors:  Antonio B Porcaro; Aldo Petrozziello; Matteo Brunelli; Filippo Migliorini; Giovanni Cacciamani; Davide De Marchi; Nicolo' de Luyk; Irene Tamanini; Beatrice Caruso; Maria A Cerruto; Claudio Ghimenton; Walter Artibani
Journal:  Asian J Urol       Date:  2015-11-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.